Biofrontera Inc. (BFRI)

Market Cap	7.58M
Revenue (ttm)	35.36M
Net Income (ttm)	-12.84M
Shares Out	7.75M
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,154
Open	0.980
Previous Close	1.000
Day's Range	0.960 - 1.055
52-Week Range	0.610 - 3.900
Beta	0.39
Analysts	Strong Buy
Price Target	7.00 (+615.38%)
Earnings Date	Nov 13, 2024

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate seve...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Oct 29, 2021
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: BFRI
• Website: https://www.biofrontera-us.com

Financial Performance

In 2023, Biofrontera's revenue was $34.07 million, an increase of 18.82% compared to the previous year's $28.67 million. Losses were -$20.13 million, 3045.5% more than in 2022.

Analyst Forecast

According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(615.38% upside)

Analyst Consensus: Strong Buy